Chuah Y.-Y.Wu D.-C.Chuah S.-K.JYH-CHIN YANGLee T.-H.Yeh H.-Z.Chen C.-L.Liu Y.-H.Hsu P.-I.2022-03-042022-03-0420171083-4389https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014146914&doi=10.1111%2fhel.12380&partnerID=40&md5=158d5e0233be786018c57da1666d02b9https://scholars.lib.ntu.edu.tw/handle/123456789/596497Objective: The aims of the study were: 1, to survey the most popular anti-H.?pylori regimens in Asia-Pacific region and the real-world effectiveness of these regimens; and 2, to investigate the expectation gaps of eradication rate between physicians and patients. Design: A questionnaire was distributed to Asia-Pacific physicians who attended the Asia-Pacific Digestive Week 2015 meeting. Reported eradication rates from the literatures were compared with real-world rates of surveyed popular regimens within the region. In addition, a questionnaire was distributed to H.?pylori-infected patients in three regions of Taiwan. Results: A total of 691 physicians and 539 patients participated in the survey. The top five most commonly used regimens were 7-day clarithromycin-based standard triple therapy (50.4%), 14-day clarithromycin-based standard triple therapy (31.0%), 10-day sequential therapy (6.1%), 14-day bismuth quadruple therapy (3.9%), and 14-day hybrid therapy (3.6%). All countries except for China had a significant gap between the expectation of physicians on anti-H.?pylori therapy and the real-world eradication rate of most commonly adopted regimens (all P value <.05). The expectation on minimal eradication rate among patients was higher than that of physicians (91.4% vs 86.5%, P<.001). Conclusions: It is time for physicians in Asia-Pacific countries to adopt newer and more efficacious anti-H.?pylori regimens to meet the Kyoto consensus recommendation and their patients’ expectations. ? 2017 John Wiley & Sons Ltdexpectation; Helicobacter pylori eradication; real-world practice[SDGs]SDG3bismuth; clarithromycin; antiinfective agent; Article; China; clinical effectiveness; clinical practice; cost benefit analysis; doctor patient relation; drug effect; eradication therapy; expectation; health insurance; Helicobacter infection; human; major clinical study; Taiwan; treatment duration; treatment planning; Asia; clinical practice; cross-sectional study; drug therapy; female; Helicobacter infection; male; Pacific islands; procedures; questionnaire; treatment outcome; Anti-Bacterial Agents; Asia; Cross-Sectional Studies; Drug Therapy; Female; Helicobacter Infections; Humans; Male; Pacific Islands; Practice Patterns, Physicians'; Surveys and Questionnaires; Treatment Outcomejournal article10.1111/hel.12380282442642-s2.0-85014146914